Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor.
Williams
John
J
Lim
Robert
R
Tambyah
Paul
P
D000666:Amphotericin B / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000139:chemically induced* / Q000188:drug therapy; D000068258:Bevacizumab; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000068258:Bevacizumab; D017964:Itraconazole; D000666:Amphotericin B